Braveheart Bio, Inc.
BRVEHealthcare|Biotechnology|US
$18.60
+1.19 (+6.80%)
About
Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.
Stock Price
-37.6%(1Y)
1M
-2.6%
3M
-38.0%
6M
-37.6%
YTD
-37.6%
1Y
-37.6%
3Y
-37.6%
5Y
-37.6%
Pipeline Summary
1 total trials0
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
Recruiting: 1
Active Trials (1)
BHB-1893 Versus Metoprolol for Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT07755904Cardiomyopathy, Hypertrophic Obstructive
Phase 3Recruiting
Enrollment: 210 participants
Key Facts
Market Cap$1.31B
Employees49
CEOTravis Murdoch
IPO DateAug 6, 2026
Beta0.00
52-Week Range$16.7 – $32
Avg Volume497,718
ExchangeNASDAQ
Websitebraveheart.bio
Ownership
Shares Outstanding70.7M
Recent Insider Trades
Agarwala VineetaOTHER
Aug 7, 20260 shares
AH Bio Fund IV, L.P.BUY
Aug 7, 20261,100,000 shares @ $18.00
AH Bio Fund IV, L.P.CONVERSION
Aug 7, 20269,132,420 shares
AH Bio Fund IV, L.P.CONVERSION
Aug 7, 202640,000,000 shares
Chimovits ErezBUY
Aug 7, 20261,666,667 shares @ $18.00
Peers
Recent News
Braveheart Bio, Inc. (BRVE) Shareholder/Analyst Call Transcript
Nov 6, 2026 · seekingalpha.com
Braveheart Bio Shares One-Year Heart Drug Data, Plans New Fixed-Dose Trial
Nov 6, 2026 · marketbeat.com
Hengrui Pharma and Braveheart Bio Present Data from 52-Week Open-Label Extension of Phase 2 Study of HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at American Heart Association Scientific Sessions 2026
Nov 6, 2026 · globenewswire.com
Braveheart Bio to Host Webinar – HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor – with Key Opinion Leader Discussion on November 6, 2026
Oct 30, 2026 · globenewswire.com
Braveheart Bio Announces Upcoming Presentations at the American Heart Association Scientific Sessions 2026
Oct 30, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 04:00 AM